Clinuvel Analyses From U.S. Study Show ‘Dramatic Improvement’

Clinuvel Pharmaceuticals Ltd. (CUV) said analyses of its Phase II U.S. study in EPP has shown patients who recieved the active drug were able to spend more time in direct sunlight.

To contact the editor responsible for this story: Malcolm Scott at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.